Collectively, these emerging therapeutic modalities—including CD73 inhibition, dual adenosinergic targeting, EV-based interventions, and Treg reprogramming—offer promising avenues to refine melanoma immunotherapy. This evidence concerns the gene NT5E and melanoma.